MASH / MASLD

Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.

Key hepatology updates from March 2026, including a first-in-class PBC therapy, viral hepatitis insights, and emerging research in MASLD and HCC.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

New research suggests MASLD risk may develop early in life, highlighting the impact of parental factors and cumulative childhood adiposity.

Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.

An audio recap of the top 5 stories in healthcare news from the week of 02/15-02/21.

Positive results from a follow-up preclinical study of Thykamine show dose-dependent effects on key pathological hallmarks of MASH.

Younossi emphasizes the need for NIT-based risk stratification for MASLD, citing his research supporting their widespread adoption across clinical settings.

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.

Catch up on hepatic FDA news, expert insights on PBC and MASH developments, & more.

Nancy Reau, MD, and Kimberly Brown, MD, discuss the challenges of accurately assessing and addressing alcohol use in patients with MASLD.

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

The Q4 recap for hepatology spotlights new AASLD guidelines, changes to CDC hepatitis B vaccination recommendations, and more.

The designation follows positive phase 2b data and FDA alignment on a phase 3 trial.

Catch up on new infant hepatitis B vaccine recommendations, liver transplant guidelines, research on GLP-1 RAs, and more.

The hepatology year in review highlights FDA approvals, MASH therapies, viral hepatitis advances, cholestatic disease shifts, and evolving clinical guidance.

The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.

Positive topline results from the phase 2b IMPACT trial show statistically significant improvements in key noninvasive tests with pemvidutide.

Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.

Catch up on new AASLD MASH guidelines on semaglutide, key research from The Liver Meeting 2025, and more.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

Patients with MASLD, advanced CKM stages face higher mortality and liver fibrosis, emphasizing the need for early risk assessment.

Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than those with overweight or obesity but without MASLD.

Alkhouri explains the importance of differentiating F3 from cirrhosis and the utility of different noninvasive tests for identifying these patients.